CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

307 papers

Showing 25-36 of total 307 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedSupporting evidence

Microfluidic-based rapid generation of chimeric antigen receptor T cells improves low-multiplicity-of-infection transduction efficiency while preserving functional activity.

2026PubMedDirectly related

The Current Landscape and Prospects of iPSCs in BCMA-targeted Therapy for Multiple Myeloma.

Wu M; Pan X; Zhong Y; Ke M; Wu Y

Jan 1, 2026Current stem cell research & therapy

2026PubMedDirectly related

Efficacy of CAR-T-Cell-Based Immunotherapies in Patients With Glioma: A Systematic Review and Meta-Analysis.

Zadeh SMM; Kalantari S; Dastgerdi SS; Sharifi H; Mohammadi M; Roudi R; Shariftabrizi A; Kalantari A; Ahmadvand D; Yazdi M; Nedaeinia R

Jan 1, 2026Journal of cellular and molecular medicine

2026PubMedDirectly related

Academic manufacturing of anti-CD19 CAR-T cells from a leukapheresis with a high proportion of acute myeloid leukaemia blasts.

Cuffel A; Bisson A; Ruminy P; Rainville V; Dehayes J; Fleury A; Blondel C; Maho-Vaillant M; Boutet C; Saada V; Lobrano C; Giverne C; Martinet J; Boyer O; Latouche JB

Jan 1, 2026Current research in translational medicine

2026PubMedDirectly related

Physical Recovery After CAR-T Cell Therapy vs. Autologous Stem Cell Transplantation Assessed Through Quantitative Rehabilitation Measures.

Feri F; Hutsava Y; Monico R; Morena F; Perriello VM

Jan 1, 2026Biomedicines

2026PubMedDirectly related

Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy.

Bangolo A; Gill S; Zhang L; Zhao J; Amoozgar B; Reich-Slotky R; Tran J; Vo T; Mariblanca G; Balulescu X; Mcknight S; Patel N; Reed A; Kaur S; Subramanian S; Katyal J; Manikkuttiyil C; Chakov M; Nguyen A; Pashine S; Khalil A; Mathew S; Gill R; Andrews V; Ordonez P; Olson B; Koleng M; Persaud R; Saride HS; Dharsi M; Thach R; Chen W; Shahid M; Weissman S; Siegel D; Parmar H; Biran N; Vesole DH; Phull P

Jan 1, 2026World journal of experimental medicine

2026PubMedSupporting evidence

Computational design of optimized and preferentially paired human TCR constant regions for improved T cell function.

Radman M; Shamul-Raybi A; Parker J; Fleishman SJ; Cohen CJ

Jan 1, 2026Science advances

2026PubMedDirectly related

Beyond CAR-T: Preventing and Treating Relapse in B-Cell Haematological Malignancies.

Canichella M; Abruzzese E; Cefalo M; Gianfelici V; Mazzone C; Trotta GE; Laureana R; Cupelli L; Del Principe MI

Jan 1, 2026Cells

2026PubMedSupporting evidence

Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.

Jallouk AP; Ge Z; Kaimal V; Zhang K; Lauron EJ; Robbins PB; Roberts ZJ; Danson E; Richard MD; Devashish P; Neelapu SS; Bachireddy P

Jan 1, 2026Cancer discovery

2026PubMedDirectly related

From Delivery to Design: Site-Specific Genome Engineering for Next-Generation CAR T-Cell Therapy.

Aldahshan H; Al-Hubaysh A; Alrabiah DK; Alturki M; Alkharji RR; Lin S; Aldughaim MS; Albugami R

Jan 1, 2026Biomedicines

2026PubMedDirectly related

Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer.

Gupta MK; Vadde R; Nagaraju GP

Jan 1, 2026MedComm

2026PubMedSupporting evidence

Genome-Wide Integration Site Profiling of Multi-Component CAR T-Cell Engineering Systems with ADA1/CD26 Co-Transduction.

Song K; Hu Y; Song X

Jan 1, 2026Biomedicines